Emboa Medical
Develops a nature-inspired catheter intended to improve extraction of cerebral blood clots in ischemic stroke. The company focuses on biomimetic device design to increase clot extraction forces across catheter sizes and advances the technology through academic partnerships, prototyping, validation, and participation in medtech accelerator and grant programs.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Biomimetic thrombectomy aspiration catheter
A nature-inspired catheter designed to increase blood clot extraction forces for treatment of ischemic stroke, intended to restore cerebral blood flow by removing occlusive clots.
Biomimetic thrombectomy aspiration catheter
A nature-inspired catheter designed to increase blood clot extraction forces for treatment of ischemic stroke, intended to restore cerebral blood flow by removing occlusive clots.
Services
Partnerships and licensing arrangements with academic institutions to develop and transfer device technology.
Engagement with accelerator cohorts and pursuit of grants and prizes to advance device development and commercialization readiness.
Partnerships and licensing arrangements with academic institutions to develop and transfer device technology.
Engagement with accelerator cohorts and pursuit of grants and prizes to advance device development and commercialization readiness.
Expertise Areas
- Endovascular device development
- Biomimetic engineering for medical devices
- Preclinical device validation
- Technology licensing and academic partnerships
Key Technologies
- Catheter-based thrombectomy
- Biomimetic design principles
- Endovascular device prototyping
- Preclinical validation methods for devices
News & Updates
Selected to the Medtech Innovator 2025 cohort (top percentile of applicants).
Selected to the Ray of Hope Accelerator cohort for nature-inspired approaches to improve thrombectomy.
Awarded manufacturing grant support (Fuzehub Manufacturing Grant winners).
Executed a licensing agreement with Purdue University related to the catheter technology.
Selected for the NIH Blueprint Medtech Seedling Program to support medtech translation.
Winner of a startup prize in the FDA track (program participation/award).
Selected to the Medtech Innovator 2025 cohort (top percentile of applicants).
Selected to the Ray of Hope Accelerator cohort for nature-inspired approaches to improve thrombectomy.
Awarded manufacturing grant support (Fuzehub Manufacturing Grant winners).
Executed a licensing agreement with Purdue University related to the catheter technology.
Selected for the NIH Blueprint Medtech Seedling Program to support medtech translation.
Winner of a startup prize in the FDA track (program participation/award).